<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663609</url>
  </required_header>
  <id_info>
    <org_study_id>C1073-450</org_study_id>
    <nct_id>NCT02663609</nct_id>
  </id_info>
  <brief_title>Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome</brief_title>
  <acronym>RE-KLAIM</acronym>
  <official_title>Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chart review study to collect patient data from medical charts of patients who have been&#xD;
      treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective, multi-center, chart review study to collect patient data from medical charts&#xD;
      of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal&#xD;
      Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with&#xD;
      follow-up of a minimum 3 months. Only sites that have been identified to have patients&#xD;
      appropriate for this protocol will be invited to participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Utilization Patterns as assessed by chart review</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The retrospective review would analyze the drug utilization patterns of patients treated with Korlym</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcomes as assessed by chart review</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The retrospective review would analyze outcomes measures (vitals, clinical assessments, etc) in patients treated with Korlym</description>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Cushing's Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No treatment (intervention) was administered.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ACTH Independent Cushing's Syndrome patients treated with Korlym® mifepristone) as standard&#xD;
        of care in clinical practice.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with ACTH independent endogenous Cushing's Syndrome&#xD;
&#xD;
          -  Available adrenal imaging prior to being treated with Korlym®&#xD;
&#xD;
          -  Treated with Korlym® and followed for at least 3 months (follow-up data should be&#xD;
             available)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with adrenocortical carcinoma&#xD;
&#xD;
          -  Participant in any clinical trial(s) during the observational period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>November 29, 2018</last_update_submitted>
  <last_update_submitted_qc>November 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing's Syndrome</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>Adrenal</keyword>
  <keyword>Retrospective</keyword>
  <keyword>Chart Review</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

